Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 271

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 271
---
 changes on cash and cash equivalents and restricted cash (67,913) (9,585) Net change in cash, cash equivalents and restricted cash 5,187,119 (23,858,549) Cash, cash equivalents and restricted cash, beginning of year 10,811,056 34,669,605 Cash, cash equivalents and restricted cash, end of year $ 15,998,174 $ 10,811,056 Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash and cash equivalents $ 15,698,174 $ 10,476,056 Restricted cash included in other non-current assets 300,000 335,000 Total cash, cash equivalents and restricted cash $ 15,998,174 $ 10,811,056 Supplemental disclosure of non-cash investing and financing activities: Operating right-of-use assets obtained in exchange for new operating lease liabilities $ 358,315 $ 1,291,425 Issuance cost on equity paid in common stock $ 500,227 $ — Additions to property and equipment and reduction of deposits $ 749,036 $ — Issuance cost recorded under additional-paid-in-capital $ — $ 834,510 See accompanying notes. F-7

Daré Bioscience, Inc. and Subsidiaries Notes to Consolidated Financial Statements 1. ORGANIZATION AND DESCRIPTION OF BUSINESS Daré Bioscience, Inc. is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré Bioscience, Inc. and its wholly-owned subsidiaries operate one segment. In this report, the “Company” refers collectively to Daré Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. The Company began assembling its diverse portfolio of assets in 2017 through acquisitions, exclusive in- licenses and other collaborations. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause, and aim to enhance outcomes and convenience. The Company’s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval. The Company's portfolio of product candidates includes drug and drug/device product candidates and potential product candidates in various stages of development. The first U.S. Food and Drug Administration (FDA